US 12,084,519 B2
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
Charles B. Shoemaker, Medford, MA (US); and Hanping Feng, Medford, MA (US)
Assigned to Trustees of Tufts College, Medford, MA (US)
Filed by TRUSTEES OF TUFTS COLLEGE, Medford, MA (US)
Filed on Jul. 9, 2021, as Appl. No. 17/371,762.
Application 14/665,542 is a division of application No. 13/566,524, filed on Aug. 3, 2012, granted, now 9,023,352, issued on May 5, 2015.
Application 17/371,762 is a continuation of application No. 15/475,664, filed on Mar. 31, 2017, granted, now 11,091,563.
Application 15/475,664 is a continuation of application No. 14/665,542, filed on Mar. 23, 2015, granted, now 9,834,616, issued on Dec. 5, 2017.
Application 13/566,524 is a continuation in part of application No. 12/889,511, filed on Sep. 24, 2010, granted, now 8,349,326, issued on Jan. 8, 2013.
Application 12/889,511 is a continuation in part of application No. 12/032,744, filed on Feb. 18, 2008, granted, now 8,865,169, issued on Oct. 21, 2014.
Claims priority of provisional application 61/514,949, filed on Aug. 4, 2011.
Claims priority of provisional application 60/890,626, filed on Feb. 20, 2007.
Prior Publication US 2021/0363275 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/16 (2006.01); A61K 39/395 (2006.01); C07K 16/12 (2006.01); C07K 16/40 (2006.01); C07K 16/44 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/468 (2013.01) [A61K 38/16 (2013.01); A61K 39/39591 (2013.01); C07K 16/1282 (2013.01); C07K 16/40 (2013.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/31 (2013.01); C07K 2317/569 (2013.01); C07K 2317/62 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/40 (2013.01)] 24 Claims
 
1. A composition comprising at least one VHH polypeptide or at least one functional binding fragment thereof, wherein the at least one VHH polypeptide or the at least one functional binding fragment thereof binds to Clostridium difficile toxin B and wherein the at least one VHH polypeptide comprises:
(a) an amino acid sequence comprising SEQ ID NO: 67, wherein the amino acid sequence of SEQ ID NO: 67 comprises SEQ ID NO: 16 at its amino terminus and SEQ ID NO: 18 at its carboxy terminus;
(b) an amino acid sequence comprising SEQ ID NO: 68, wherein the amino acid sequence of SEQ ID NO: 68 comprises SEQ ID NO: 16 at its amino terminus and SEQ ID NO: 18 at its carboxy terminus; or
(c) an amino acid sequence comprising SEQ ID NO: 69, wherein the amino acid sequence of SEQ ID NO: 69 comprises SEQ ID NO: 16 at its amino terminus and SEQ ID NO: 18 at its carboxy terminus.